Guardant Health makes blood tests that find cancer DNA, helping doctors pick treatments and spot early signs of the disease.
Money comes from selling its Guardant360 and other liquid biopsy tests, with a gross margin around 65% but the company still loses money overall.
Their large database of cancer mutations and FDA-approved tests create a barrier, but Exact Sciences and Natera are pushing into similar territory, making the moat eroding.
Buy (sector percentile 83) — value C-, growth B, profitability A, momentum A-, revisions A-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Q2 EPS loss of $0.42 missed by $0.02, but revenue beat and full-year guidance raised
Company announced participation in Canaccord Genuity and other investor conferences, a routine corporate update.
Multiple independent sources confirm GH's 52-week high breakout and inclusion in leading stock scans, extending prior uptrend
None yet
None yet
Guardant Health ($GH) is identified as a stock meeting the 'Trend Template' criteria, suggesting a potential upward trend based on technical analysis. The discussion is focused on identifying stocks within this technical framework.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
